Literature DB >> 20062939

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.

Gregory Y H Lip1, Kurt Huber, Felicita Andreotti, Harald Arnesen, K Juhani Airaksinen, Thomas Cuisset, Paulus Kirchhof, Francisco Marín.   

Abstract

There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20062939     DOI: 10.1160/TH09-08-0580

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  50 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

2.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  [Dual platelet inhibitors in intensive care units].

Authors:  J M Siller-Matula; G Delle Karth
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-07-03       Impact factor: 0.840

4.  Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery.

Authors:  Javier A Valle; Laura Graham; Aerin DeRussy; Kamal Itani; Mary T Hawn; Thomas M Maddox
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

5.  [Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants].

Authors:  Ingrid Pabinger; Wilfried Lang; Franz Xaver Roithinger; Franz Weidinger; Sabine Eichinger-Hasenauer; Reinhold Glehr; Walter-Michael Halbmayer; Hans-Peter Haring; Bernd Jilma; Hans Christian Korninger; Sibylle Kozek-Langenecker; Paul Kyrle; Herbert Watzke; Ansgar Weltermann; Johann Willeit; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2014-10-03       Impact factor: 1.704

6.  Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome.

Authors:  W Schuyler Jones; Xiaojuan Mi; Manesh R Patel; Roger Mills; Adrian F Hernandez; Lesley H Curtis
Journal:  Clin Cardiol       Date:  2013-12-11       Impact factor: 2.882

Review 7.  Atrial fibrillation: state of the art.

Authors:  Matthias Hasun; Eduard Gatterer; Franz Weidinger
Journal:  Wien Klin Wochenschr       Date:  2014-11-20       Impact factor: 1.704

Review 8.  Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation.

Authors:  Mahesh V Madhavan; Ajay J Kirtane
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

9.  Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study.

Authors:  Hisao Otsuki; Junichi Yamaguchi; Kazuho Kamishima; Hiroyuki Arashi; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2018-03-16       Impact factor: 2.037

Review 10.  The challenge of antiplatelet therapy in patients with atrial fibrillation and heart failure.

Authors:  Yutao Guo; Gregory Y H Lip; Stavros Apostolakis
Journal:  J Cardiovasc Transl Res       Date:  2012-12-04       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.